# China NMPA Drug Inspection - Anhui Fangshi Pharmaceutical Co., Ltd. - Arrowroot

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/anhui-fangshi-pharmaceutical-co-ltd/fd172848-5e13-4bdb-a72f-01075e986626/
Source feed: China

> China NMPA drug inspection for Anhui Fangshi Pharmaceutical Co., Ltd. published November 27, 2020. Drug: Arrowroot. The Shanxi Provincial Drug Administration published an announcement on November 27, 2020, regarding the results of its a

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement from Shanxi Provincial Drug Administration Regarding 9 Batches of Drugs That Failed to Meet Regulations
- Company Name: Anhui Fangshi Pharmaceutical Co., Ltd.
- Publication Date: 2020-11-27
- Drug Name: Arrowroot
- Inspection Finding: The "sulfur dioxide residue" item did not meet the requirements.
- Action Taken: The drug regulatory authorities have conducted investigations and taken action in accordance with the law, and the relevant enterprises and units have taken risk control measures such as suspending sales and use and recalling products.
- Summary: The Shanxi Provincial Drug Administration published an announcement on November 27, 2020, regarding the results of its annual drug quality sampling inspections. These inspections focused on drug production, distribution, and use units to ensure public medication safety. The report identified nine batches of substandard drugs from several manufacturers. Notable companies include Bozhou Jingwan Traditional Chinese Medicine Pieces Factory, Shanxi Pikang Pharmaceutical Co., Ltd., Anhui Fangshi Pharmaceutical Co., Ltd., Anguo Anxing Traditional Chinese Medicine Pieces Co., Ltd., Anhui Huadingtang Traditional Chinese Medicine Pieces Technology Co., Ltd., and Bozhou Zhongqiang Traditional Chinese Medicine Pieces Co., Ltd. The main violations found during the testing included failed extractives tests, excessive microbial limits in capsule medications, and illegal sulfur dioxide residues in herbal products. Furthermore, several batches of traditional Chinese medicine pieces failed basic appearance standards. These issues represent significant deviations from the quality regulations established by the National Medical Products Administration (NMPA). In response to these findings, the Shanxi Provincial Drug Administration has initiated formal investigations into the non-compliant drugs. The involved companies and healthcare facilities are required to implement immediate risk control measures. These actions include the suspension of sales, the cessation of clinical use, and the mandatory recall of the affected product batches. These regulatory steps are designed to mitigate health risks and hold manufacturers accountable for maintaining strict quality control standards across the pharmaceutical supply chain.

Company: https://www.globalkeysolutions.net/companies/anhui-fangshi-pharmaceutical-co-ltd/7338ada3-7694-47b6-9e9a-652cbfb5dda9/